Skip to content

Behzad Aghazadeh, Director at Scribe Therapeutics, bought SCTX on Jul 28, 2026

Data as of Oct 16

▲ BUY$144K7,905 shares at $18.25Behzad Aghazadeh DirectorSCTX Scribe Therapeutics, Inc.
Watch SCTX
Traded
Jul 28, 2026
Disclosed
Jul 28, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Behzad Aghazadeh, Director at Scribe Therapeutics, bought SCTX on Jul 28, 2026TRADEDDISCLOSED
SCTXSimilar stocks (XLV — its sector index fund), rebased to SCTX's price on the disclosure day
SCTX since disclosure
+11.2%
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund

Change in closing price from Jul 28, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▲ BUYAvoro Ventures LLC DirectorSCTX Scribe Therapeutics, Inc.$144Kdisclosed Jul 28 · filed the same day
  2. ▲ BUYAvoro Capital Advisors LLC DirectorSCTX Scribe Therapeutics, Inc.$144Kdisclosed Jul 28 · filed the same day
  3. ▲ BUYAvoro Ventures LLC DirectorSCTX Scribe Therapeutics, Inc.$35Mdisclosed Jul 28 · filed 4 days after the trade
  4. ▲ BUYBehzad Aghazadeh DirectorSCTX Scribe Therapeutics, Inc.$1.1Mdisclosed Jul 28 · filed 4 days after the trade
  5. ▲ BUYAvoro Capital Advisors LLC DirectorSCTX Scribe Therapeutics, Inc.$35Mdisclosed Jul 28 · filed 4 days after the trade
  6. ▲ BUYBehzad Aghazadeh DirectorSCTX Scribe Therapeutics, Inc.$35Mdisclosed Jul 28 · filed 4 days after the trade
  7. ▲ BUYAvoro Ventures LLC DirectorSCTX Scribe Therapeutics, Inc.$1.1Mdisclosed Jul 28 · filed 4 days after the trade
  8. ▲ BUYAvoro Capital Advisors LLC DirectorSCTX Scribe Therapeutics, Inc.$1.1Mdisclosed Jul 28 · filed 4 days after the trade

See every trade on SCTX →